Topotecan: An oncologist's view

Oncologist

Volumn 3, Issue 6, 1998, Pages 390-402

  Héron, Jean François ^a  

^a CENTRE FRANÇOIS BACLESSE   (France)

Author keywords

Clinical trials; Leukemia; Ovarian neoplasms; Review; Small cell lung carcinoma; Topotecan

Indexed keywords

CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; PACLITAXEL; TOPOTECAN; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLON CANCER; DRUG EFFICACY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; NEUTROPENIA; ORAL DRUG ADMINISTRATION; OVARY CANCER; PRIORITY JOURNAL; SOLID TUMOR;

EID: 0032441820     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.3-6-390     Document Type: Article

References (18)

1. Eckardt J, Eckhardt G, Villalona-Calero M et al. New anticancer agents in clinical development. Oncology 1995;9:1191-1199.
2. Xie Z-F, Ootsu K, Akimoto H. Convergent approach to water soluble camptothecin derivatives. Bioorg Med Chem Lett 1995;5:2189-2194.
3. Kingsbury WD, Boehm JC, Jakas DR et al. Synthesis of water-soluble (aminoalkyl) camptothecin analogs: inhibition of topoisomerase I and antitumor activity. J Med Chem 1991;34:98-107.
4. Hsiang Y-H, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989;49:5077-5082.
5. Burris HA III, Hanauske A-R, Johnson RK et al. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst 1992;84:1816-1820.
6. Johnson RK, McCabe FL, Gallagher G et al. Comparative efficacy of topotecan, irinotecan, camptothecin and G-amino-camptothecin in preclinical tumour models. Proc 7th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam 1992:85.
7. Houghton PJ, Cheshire PJ, Myers L et al. Evaluation of 9-dimethyl-aminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 1992;31:229-239.
8. Mattern MR, Hofmann GA, Polsky RM et al. In vitro and in vivo effects of clinically important camptothecin analogs on multidrug-resistant cells. Oncol Res 1993;5:467-474.
9. Hendricks CB, Rowinsky EK, Grochow LB et al. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analog. Cancer Res 1992;52:2268-2278.
10. Wall JG, Burris HA III, Von Hoff DD et al. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anticancer Drugs 1992;3:337-345.
11. Rowinsky EK, Grochow LB, Hendricks CB et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 1992;10:647-656.
12. Herben VMM, ten Bokkel Huinink WW, Beijnen JH. Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 1996;31:85-102.
13. Armstrong D, O'Reilly S. Clinical guidelines for managing topotecan-related hematologic toxicity. The Oncologist 1998;3:4-10.
14. Verweij J, Lund B, Beijnen J et al. Phase I and pharmacokinetic study of topotecan, a new topoisomerase I inhibitor. Ann Oncol 1993:4:673-678.
15. Saltz L, Sirott M, Young C et al. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumours, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst 1993;85:1499-1507.
16. Rowinsky E, Sartorius S, Grochow L et al. Phase I and pharmacologic study of topotecan, an inhibitor of topoisomerase I, with granulocyte colony-stimulating factor (G-CSF): toxicologic differences between concurrent and post-treatment G-CSF administration. Proc ASCO 1992;11:284.
17. Rowinsky EK, Grochow LB, Sartorius SE et al. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors. J Clin Oncol 1996;14:1224-1235.
18. O'Reilly S, Rowinsky EK, Slichenmyer W et al. Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol 1996;14:3062-3073.